You are here

KS-Detect: A solar-powered and smartphone integrated instrument for point-of-care diagnosis of Kaposi's sarcoma

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA193096-01
Agency Tracking Number: R43CA193096
Amount: $224,835.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 102
Solicitation Number: PAR13-327
Timeline
Solicitation Year: 2016
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-01-20
Award End Date (Contract End Date): 2015-06-30
Small Business Information
2605 BRIDLE PATH RD
Norristown, PA 19403-3954
United States
DUNS: 079352545
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 LI JIANG
 (262) 224-4501
 jiang.li2284@gmail.com
Business Contact
 DAVID ERICKSON
Phone: (607) 342-1799
Email: daviderickson@aasinc.co
Research Institution
N/A
Abstract

DESCRIPTION provided by applicant Aandapos as pronounced Ah z in collaboration with Cornell University and Weill Cornell Medical College aims to commercialize a solar powered and smartphone integrated system for performing nucleic acid based analysis of Kaposiandapos s sarcoma herpesvirus in limited resource settings Our andquot KS Detectandquot system comprises of an instrument that performs PCR through solar heating of a microfluidic chip a small traveling case that contains the instrument and can be carried by a clinician to the patient and a smartphone andquot appandquot that reads the on chip temperatures operates sample flow inside the chip and interprets the fluorescence signal of the sample to provide the user with the test results KS is one of the most prevalent cancers in sub Saharan Africa and is associated with high mortality rates Often patients are not diagnosed until they develop later stages of the disease when available therapeutics lose much of their potency In the absence of immunohistochemistry polymerase chain reaction PCR identification of Kaposiandapos s sarcoma associated herpesvirus KSHV in skin biopsies represents the most reliable method of diagnosing a patient Unfortunately existing technologies cannot address the needs associated with biopsy based nucleic acid screening in limited resource settings As part of the $ B nucleic acid test market new instruments must be cost effective and portable in order to provide early on site diagnosis for those who cannot access care at centralized facilities The technologies behind KS Detect which were developed at Cornell University allow PCR based diagnostics to be performed on tissue samples in the field without the need for expensive equipment or reliable electrical power This is achieved through the incorporation of andquot lab on a syringeandquot tissue processing solar thermal PCR and smartphone based operation and diagnostics A prototype was built and tested in Kenya and Uganda in early In Phase I we will ruggedize the current system and perform validation tests using pseudo biopsies With NIH support we will focus on a four stage path to market plan that involves Technology development building off preliminary results Human trials in collaboration with Weill Cornell AMPATH and the Infectious Diseases Institute System deployment in large scale human studies and Product release to healthcare providers and other foundations

PUBLIC HEALTH RELEVANCE Kaposiandapos s sarcoma is one of the most prevalent cancers in sub Saharan Africa and is associated with high mortality rates due to extremely limited access to nucleic acid based tests in the developing world In this proposal Aandapos as seeks to develop a solar powered and smartphone integrated instrument for performing polymerase chain reaction in limited resource settings This low cost and power efficient system can be used by traveling clinicians as well as central labs

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government